Amylyx Pharmaceuticals Inc (AMLX)
1.745
-0.04
(-1.97%)
USD |
NASDAQ |
Apr 26, 13:53
Amylyx Pharmaceuticals Cash from Investing (TTM): 92.05M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 92.05M |
| September 30, 2023 | -157.05M |
| June 30, 2023 | 35.08M |
| March 31, 2023 | -83.68M |
| December 31, 2022 | -238.99M |
| Date | Value |
|---|---|
| September 30, 2022 | -7.994M |
| June 30, 2022 | -141.24M |
| March 31, 2022 | -145.70M |
| December 31, 2021 | -46.41M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-238.99M
Minimum
Dec 2022
92.05M
Maximum
Dec 2023
-77.10M
Average
-83.68M
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
| Cassava Sciences Inc | -0.414M |
| iRhythm Technologies Inc | -1.209M |
| Bristol-Myers Squibb Co | -2.295B |
| Moderna Inc | 4.206B |
| ACADIA Pharmaceuticals Inc | 32.00M |